Q3C(R8)
GUIDELINE FOR RESIDUAL SOLVENTS
Q3C(R8)
Q3C(R8)
A buffer solution is an acid or a base aqueous solution consisting of a mixture of a weak acid and its conjugate base, or vice versa. Its pH changes very little when a small amount of strong acid or base is added to it
The linearity of an analytical procedure is its ability (within a given range) to obtain test results which are directly proportional to the concentration (amount) of analyte in the sample.
HPLC
Going into more detail, HPLC consists of a variety of components, including a solvent delivery pump, a degassing unit, a sample injector, a column oven, a detector, and a data processor.
GC
GC uses an inert or unreactive carrier gas as the mobile phase, and the stationary phase is generally a thin layer of liquid. As the mobile phase moves, it separates the mixture into its individual components in the stationary phase
Mass spectrometry (MS) is an analytical technique that separates ionized particles such as atoms, molecules, and clusters by using differences in the ratios of their charges to their respective masses (mass/charge; m/z), and can be used to determine the molecular weight of the particle
between 4000 – 670cm–1
Iodometry is a titration in which the reducing agent is utilised to titrate the iodine formed in the preceding redox reaction, whereas iodimetry is a titration in which the reducing agent is used to titrate the iodine solution directly.
A back titration is a titration method where the concentration of an unknown compound is determined by reacting with a known amount of excess reagent. A back titration is also called indirect titration. There is a chemical reaction between these compounds.
Aurobindo Pharma on Tuesday said the US health regulator has issued Form 483 with three observations after inspecting its manufacturing facility at Pydibhimavaram in Andhra Pradesh.
As per US Food and Drug Administration (USFDA), Form 483 is issued to a firm’s management at the conclusion of an inspection when the investigator has observed any conditions that in its judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
The Pydibhimavaram unit was classified as OAI (official action indicated) on May 17, 2019, and subsequently given a warning letter on June 20, 2019 by the USFDA, Aurobindo Pharma said in a regulatory filing.
Subsequently, the company said it has responded to the warning letter and carried out the committed corrections and the USFDA authorities inspected the facility from July 25 to August 2, 2022.
”At the end of the inspection, we have been issued a Form 483 with three observations and none of these observations are related to data integrity,” Aurobindo Pharma said.
The company will respond to the USFDA within the stipulated timeline and work closely with the regulator to address the observations at the earliest, it added.
The unit is a non-antibiotic active pharmaceutical ingredients manufacturing facility.
Links observation
• Method: method validation
VIM
• Measurement procedure: procedure validation
GLP
• Standard operation procedure: SOP validation